Over the past decade, savings from biosimilars have grown; however, there remain barriers that prevent biosimilar savings from reaching their full potential, according to a report from the Association for Accessible Medicines.
A new report from the Association for Accessible Medicines (AAM) found that despite obstacles standing in the way of biosimilar uptake in the United States, savings from biosimilar are steadily growing and totaled $2.2 billion in 2019.
Additionally, biosimilars have achieved $4.5 billion in savings since 2010, which was when the Biologics Price Competition and Innovation Act containing the regulatory pathway for biologics was enacted.
Although biosimilar savings are growing, biosimilars still face several hurdles to uptake including lack of education, lack of reimbursements, anticompetitive practices by reference product companies, interchangeability restrictions, patent litigations and settlements, incentives to prescribe reference products, and payer formulary restrictions.
Since 2010, patients have had limited access to biosimilars. Currently, only 17 biosimilars out of the 28 FDA-approved products have launched on the US market, which could be limiting potential savings, according to the report.
“Biosimilars are projected to save America tens of billions of dollars over the next decade, but only if patients can access them….Greater use of these medicines…could generate even more savings,” wrote the authors of the report.
In the report, AAM detailed several ways to help biosimilars achieve more savings quicker.
Addressing Incentives Issues
The authors of report also discussed the lack of competition that currently exists in the US biologics’ market and called for Medicare Part D to be updated to encourage use of generics and biosimilars and include a dedicated tier for specialty generic and biosimilar medicines.
In an interview with The Center for Biosimilars®, Wayne Winegarden, PhD, senior fellow in business and economics at the Pacific Research Institute (PRI) and director of PRI’s Center for Medical Economics and Innovation discussed the importance for separate formulary tier lists for biosimilars.
“You can have certain types of criteria in terms of price discounts relative to originator price or anything you want to have in order to for a product to qualify for it. But in order to share the savings…patients, the payer, and practitioners have to benefit. And if we don't get everybody's incentives aligned to have the patient using the biosimilar, then something along that chain isn't going to work well,” said Winegarden.
Additionally, AAM called for the use of rebates for reference drugs to be eliminated as they exclude lower-priced generics and biosimilars from formulary coverage and incentivize the use of reference drugs.
AAM also suggested that state-regulated health plans should prioritize coverage of generics and biosimilars. Medicare programs tend to reward the use of reference products over lower-cost alternatives.
“Constructive policies, like ending Medicare policies that reward the use of higher-cost brand drugs, could enhance that growth as specialty medicines account for an increased share of pharmaceutical costs,” said Dan Leonard, the new CEO for the AAM, in the report.
Addressing Lack of Competitive Market
Although biosimilars are widely available in the European Union and have resulted in drastic reductions drug pricing, patent disputes and lack of competition have made it more difficult for the United States to achieve the same discounts.
“We believe…patients and payers should have choices in the marketplace, and competition from generic and biosimilar medicines gives them that choice,” wrote the authors of the report.
In the report, AAM called on policymakers to take steps to ensure a viable competitive market for biosimilars to improve access to lower-cost treatments and take action against patent disputes brought on by reference product manufacturers.
Also, AAM said that America’s trade policies should reflect US law that encourages a balance between supporting the development of innovator produces and promoting a competitive market by ensuring greater access to biosimilars and generic drugs.
“Unfortunately, this policy objective, included in the Bipartisan Congressional Trade Priorities and Accountability Act of 2015, is often absent in U.S. trade policy,” the authors wrote.
Reference
Association for Accessible Medicines. Securing our access and savings: 2020 generic drug and biosimilar access and savings in the US report. AAM website. Published September 29, 2020. Accessed September 30, 2020. https://accessiblemeds.org/sites/default/files/2020-09/AAM-2020-Generics-Biosimilars-Access-Savings-Report-US-Web.pdf.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.